Pfizer’s Acquisition Of Idun Includes Phase II Caspase Inhibitor

Idun’s lead small molecule, IDN-6556, is thought to control apoptosis (cell death) and is in Phase II trials for liver transplantation and hepatitis C. The deal is expected to close in the second quarter.